Perimenopause Symptoms: What They Are, Why They Happen, and How to Treat Them

Perimenopause is the hormonal transition that precedes a woman's final menstrual period, typically starting in the mid-40s and lasting anywhere from about two to ten years. It is not one symptom but a cluster, driven by erratic and then declining estradiol, and different women land in very different clusters: one woman's dominant problem is hot flashes, another's is insomnia, another's is vaginal dryness and recurrent UTIs, another's is new-onset anxiety. The useful clinical question is usually not "do I have perimenopause" but "which symptom cluster is dominant for me, and which treatment pathway matches that cluster and my personal risk profile."

This article is educational and does not provide individualized diagnosis or dosing. Decisions about starting, adjusting, or stopping hormone therapy should be made with a clinician who has your full history.

Perimenopause, menopause, and climacteric: getting the terms right

Perimenopause refers to the transition itself, marked by irregular cycles and hormonal fluctuation. Menopause is a single point in time, confirmed retrospectively after twelve consecutive months without a period. Postmenopause is everything after that point. "Climacteric" is an older, broader term sometimes still used in the literature to describe the entire midlife hormonal transition, and its overlap with "menopause" has been debated as more than a semantic issue because the terms carry different clinical implications for staging and treatment timing (Bonaccorsi & Reginatto, 2014 discussion of terminology, https://pubmed.ncbi.nlm.nih.gov/23998690/). This article uses "perimenopause" for the transition and "menopause" for the confirmed endpoint.

What is actually happening hormonally

Perimenopause is driven by progressive depletion of ovarian follicles. As fewer follicles remain, estradiol production becomes erratic before declining. The pituitary compensates by increasing follicle-stimulating hormone (FSH) output to try to recruit remaining follicles. The combination of FSH surges and unstable estradiol signaling produces the symptom picture most women associate with "the change."

Estradiol receptors are distributed well beyond the reproductive tract: brain, cardiovascular system, bone, bladder, vaginal epithelium, and skin. That distribution is why perimenopause produces such a wide symptom list, and why a single treatment rarely resolves every complaint a woman experiences.

The core, quotable answer: Perimenopause is the multi-year hormonal transition before the final menstrual period, driven by fluctuating and then declining estradiol with compensatory FSH elevation; it commonly produces vasomotor symptoms (hot flashes, night sweats), sleep disruption, genitourinary changes, and mood or cognitive symptoms, and most of these respond to systemic hormone therapy, targeted non-hormonal medications, or a combination, when matched to the dominant symptom and the woman's individual risk profile.

Hot flashes and night sweats

A hot flash is a sudden wave of heat, usually over the chest, neck, and face, lasting roughly one to five minutes and often followed by sweating or chills. Night sweats are the nocturnal version and directly fragment sleep. Hot flashes are widely reported to affect a large majority of women at some point during the transition, and for a meaningful minority they persist for years after the final period, though exact prevalence figures vary across studies and populations and any specific percentage should be checked against a current systematic review before being repeated as a fixed statistic.

The proposed mechanism involves the hypothalamic thermoregulatory zone. Declining estradiol appears to narrow the "thermoneutral zone," the range of core body temperature the hypothalamus tolerates without triggering a cooling response. Small temperature increases then trigger cutaneous vasodilation and sweating. Kisspeptin-neurokinin B-dynorphin (KNDy) neurons in the hypothalamic arcuate nucleus are implicated in this pathway, which is the biological rationale behind neurokinin 3 receptor antagonists as a non-hormonal treatment class.

Treatment options, ordered by where they sit in the evidence hierarchy:

• Systemic estrogen therapy (with a progestogen if the uterus is intact) is generally regarded by menopause specialty societies as the most effective treatment for moderate-to-severe vasomotor symptoms. Exact effect-size figures vary by formulation, dose, and trial, and a specific reduction percentage should not be treated as a universal number without checking the specific product label and current guideline.
• Fezolinetant is an FDA-approved neurokinin 3 receptor antagonist for moderate-to-severe vasomotor symptoms in women who cannot or choose not to use hormone therapy. Trial-level efficacy figures exist in the primary literature; readers should verify the current label and specific trial results directly rather than relying on a secondhand percentage, since regulatory and labeling details can change and this is a comparatively new drug class as of this writing (2025).
• Low-dose paroxetine (7.5 mg) is an FDA-approved non-hormonal SSRI specifically for vasomotor symptoms.
• Venlafaxine, gabapentin, and oxybutynin have supportive trial evidence for hot flash reduction but do not carry a menopause-specific FDA indication; their use for this purpose is off-label.

Lifestyle factors reported to worsen hot flashes include smoking, obesity, alcohol, caffeine, and warm ambient temperature. Addressing these is reasonable first-line advice, though the evidence that lifestyle change alone produces clinically meaningful relief in women with moderate-to-severe symptoms is limited.

Sleep disruption

Difficulty sleeping ranks among the most frequent perimenopausal symptoms, yet many patients do not receive adequate treatment. Multiple mechanisms contribute: night sweats disrupt sleep continuity, and the hormonal shifts of perimenopause (lower estradiol and progesterone) appear to reshape sleep patterns in ways that extend beyond thermal effects. Large prospective studies including the Study of Women's Health Across the Nation have documented declines in sleep efficiency during late perimenopause that persist even when hot flash frequency is controlled for; however, reported effect sizes differ between studies, so readers should consult the original papers rather than rely on a single cited figure.

Primary insomnia disorder can coexist with perimenopause and needs its own treatment path. Cognitive behavioral therapy for insomnia (CBT-I) is the first-line recommendation from sleep medicine guidelines regardless of menopausal status, but CBT-I alone may not be sufficient when night sweats are the main driver of awakenings.

A reasonable treatment ladder, to discuss with a clinician:

1. CBT-I, delivered in person or through a structured digital program.
2. Systemic hormone therapy, which addresses both the vasomotor trigger and possible direct hormonal effects on sleep architecture, if the woman is otherwise a good HRT candidate.
3. Oral micronized progesterone at bedtime, which has sedating properties through GABA-A receptor activity in some studies.
4. Low-dose doxepin, an FDA-approved option for sleep-maintenance insomnia that does not address the hormonal driver but can help bridge acute distress.
5. Melatonin, which has modest evidence for reducing time to fall asleep but weaker evidence for maintaining sleep through the night.

Genitourinary syndrome of menopause (GSM)

GSM is the term adopted by menopause specialty societies to replace the older label "atrophic vaginitis," reflecting that declining estradiol affects the urethra, bladder trigone, and pelvic floor, not only vaginal tissue. It affects a large share of postmenopausal women, and survey data consistently show that many affected women never bring it up with a clinician, which matters because GSM tends to be progressive rather than self-limiting: without treatment, vaginal pH rises, epithelial thickness decreases, and protective Lactobacillus colonization declines, producing a cycle of dryness, irritation, painful intercourse, and recurrent urinary symptoms that tends to worsen rather than resolve on its own.

Treatment options, ordered by evidence and typical first-line status:

• Low-dose vaginal estrogen (cream, ring, or tablet) is first-line for isolated GSM. Systemic absorption at approved doses is minimal, and menopause specialty guidance generally supports its use in most women, including breast cancer survivors in consultation with their oncologist, though this remains an individualized decision that should not be generalized without that consultation.
• Ospemifene, an oral selective estrogen receptor modulator, is FDA-approved for moderate-to-severe dyspareunia related to GSM.
• Prasterone, an intravaginal DHEA insert, converts locally to estradiol and testosterone and is FDA-approved for dyspareunia related to GSM.
• Over-the-counter vaginal moisturizers improve comfort but do not reverse epithelial atrophy; they are reasonable adjuncts or an option for women who decline prescription therapy.
• Lubricants help with acute friction during intercourse but have no disease-modifying effect on the underlying tissue changes.

Unlike hot flashes, which often ease with time for many women, GSM generally does not improve without some form of treatment.

Mood, anxiety, and cognitive symptoms

Estradiol is a neuroactive steroid that influences serotonin transporter expression, monoamine oxidase activity, and dopaminergic signaling, which is the proposed biological reason mood symptoms cluster around the period of greatest estradiol volatility rather than appearing only after estrogen is fully depleted. Observational cohort data describe higher rates of depressive symptoms among perimenopausal women compared with premenopausal women, with women who have a prior history of major depression or postpartum depression at meaningfully higher risk during the transition.

A 2025 qualitative study specifically examining mental health challenges during perimenopause and menopause, including suicidality, found that women in this transition described significant and sometimes under-recognized psychological distress, reinforcing that mood and safety screening should be a routine part of perimenopause care rather than an afterthought (https://pubmed.ncbi.nlm.nih.gov/40626330/). This is qualitative, exploratory evidence describing lived experience rather than a prevalence estimate, and it should not be read as establishing a specific numeric risk of suicidality in this population; it is a signal that warrants clinical attention and further quantitative research, not a settled statistic.

Cognitive complaints, particularly word-finding difficulty and short-term memory lapses, are commonly reported during the transition. Longitudinal cohort data suggest objective processing speed and verbal memory changes during late perimenopause that partially recover afterward for many women, which is consistent with the transition itself being a driver rather than permanent estrogen loss alone, though this remains an area of ongoing research rather than a settled mechanism.

A reasonable clinical approach:

• Screen for depression and anxiety (for example with the PHQ-9 and GAD-7) at perimenopausal visits, and take any mention of suicidal thinking seriously with immediate follow-up; if a woman is in crisis, urgent or emergency care is appropriate rather than waiting for a routine visit.
• Systemic HRT may improve mood in some perimenopausal women with mild depressive symptoms tied to the transition, but it is not a substitute for antidepressant treatment in women with a diagnosable depressive or anxiety disorder.
• SSRIs and SNRIs remain standard of care for clinical depression and anxiety arising during perimenopause, and can be combined with HRT when both vasomotor and mood symptoms are present, under clinical supervision.

Less commonly discussed symptoms

Several symptoms are reported in epidemiological cohorts and clinical practice but are less prominent in patient-facing material:

• Palpitations. Estradiol is thought to influence cardiac ion channels and autonomic tone, and palpitations without structural heart disease are reported by some perimenopausal women. Cardiac evaluation is still warranted before attributing palpitations to hormonal withdrawal alone, since cardiac and thyroid causes need to be excluded first.
• Joint and muscle pain. Cohort data describe increased bodily pain scores across the transition independent of BMI or activity level, with estrogen receptors on joint tissue proposed as a mechanism.
• Skin and hair changes. Estradiol supports dermal collagen synthesis, and collagen loss accelerates around the menopause transition in some studies; exact percentages vary by study and should not be quoted as a fixed figure without checking the specific source.
• Bladder urgency and recurrent UTIs. These relate to the same estrogen-sensitive urethral and bladder tissue affected in GSM, and vaginal estrogen is reported to reduce recurrent UTI frequency in postmenopausal women in some trials.
• Tinnitus, burning mouth, and altered taste. These are biologically plausible given estrogen receptors in relevant tissues, but the evidence base is sparse. These symptoms should prompt evaluation to rule out other causes before being attributed to perimenopause by default.

How perimenopause is diagnosed

There is no single blood test that confirms perimenopause. Diagnosis in women over 45 with a typical symptom pattern is primarily clinical, based on age, menstrual history, and symptom pattern; menopause specialty guidance generally recommends against routine FSH testing in this group because FSH fluctuates widely during the transition and a single normal value does not rule the diagnosis out.

When lab testing does add value:

• Age under 45 with suspected early perimenopause or premature ovarian insufficiency (POI). Elevated FSH on more than one occasion, alongside low estradiol, supports the diagnosis, but exact cutoff values and retesting intervals should come from a clinician applying current lab-specific reference ranges rather than a fixed number repeated from a general article.
• Ruling out thyroid dysfunction. TSH testing is important because both hypothyroidism and hyperthyroidism can produce hot flashes, fatigue, weight change, and mood disruption that closely mimic perimenopause.
• Ruling out pregnancy. FSH elevation in the early 40s can coexist with residual fertility, so pregnancy should not be assumed impossible based on symptoms alone.

The Stages of Reproductive Aging Workshop (STRAW) framework is a widely used staging system for the transition, generally defining early perimenopause by variable cycle length and late perimenopause by a prolonged stretch of missed periods, with twelve consecutive months of amenorrhea confirming menopause itself. Specific numeric cutoffs from this framework should be confirmed against the current published criteria rather than assumed to be static, since staging language has been refined over time.

Decision framework: matching your dominant symptom to a first step

Perimenopause treatment is not one-size-fits-all. This framework is a starting point for a conversation with a clinician, not a substitute for one.

Systemic HRT: who is generally considered a good candidate, and when

Systemic hormone therapy is widely regarded by menopause specialty organizations as the most broadly effective treatment for perimenopausal symptoms, particularly vasomotor symptoms. The "timing hypothesis," developed from re-analysis of large hormone therapy trial data, holds that cardiovascular risk associated with starting HRT differs depending on how soon after the final menstrual period treatment begins. Women who start within about 10 years of their final period or before age 60 are generally described as having a more favorable benefit-risk profile than women who start later. This is a guideline-level framework rather than a guarantee for any individual, and it should be discussed against personal cardiovascular and breast cancer risk factors.

Contraindications to systemic estrogen generally include unexplained vaginal bleeding, active or recent breast cancer, active thromboembolic disease, and active liver disease. Women with a uterus need a progestogen added to estrogen to protect the endometrium from unopposed estrogen exposure.

Transdermal estrogen avoids first-pass liver metabolism and is generally considered to carry a lower venous thromboembolism risk than oral estrogen in the literature, though exact relative-risk figures from any single study should be verified against the primary paper before being quoted as a fixed number, since risk estimates vary by study design and population.

Monitoring once treatment begins

Women starting HRT for perimenopause symptoms typically have a follow-up visit at 6 to 12 weeks to assess symptom response and side effects, then annual review thereafter. A reasonable annual review includes blood pressure measurement, age-appropriate breast cancer screening, reassessment of whether treatment is still indicated (some women's vasomotor symptoms resolve within a few years, others need longer treatment), and bone density monitoring in women with risk factors for osteoporosis.

There is no universally mandated maximum duration for HRT. The decision to continue is individualized, based on ongoing symptom burden, cardiovascular risk, breast density, and personal preference, and should be revisited periodically with a clinician rather than treated as a one-time decision.

Stopping HRT abruptly can bring back vasomotor symptoms in some women; a gradual taper is generally preferred over abrupt discontinuation to reduce rebound symptoms, though the ideal taper schedule should be individualized.

What is established, what is plausible, and what is not established

Established: Perimenopause is driven by fluctuating and declining estradiol with compensatory FSH rise. Vasomotor symptoms, sleep disruption, and GSM are well-documented consequences with FDA-approved treatment options in several categories (systemic and vaginal estrogen, fezolinetant, low-dose paroxetine, ospemifene, prasterone). GSM tends to progress without treatment. The timing hypothesis for HRT and cardiovascular risk is a recognized framework in current menopause guidelines.

Plausible but not fully settled: Specific effect-size percentages for many treatments (exact reductions in hot flash frequency, exact collagen loss percentages, exact UTI reduction rates) vary across studies and populations; they should be checked against the specific primary paper rather than treated as fixed universal numbers. The degree to which cognitive symptoms fully reverse after the transition, and the precise contribution of hormonal change versus sleep disruption versus aging to mood symptoms, remain areas of active research.

Not established from the material reviewed here: Any claim of a specific number of "lost workdays" attributable to perimenopause symptoms, and any specific numeric suicidality risk figure for perimenopausal women, are not supported by verified primary sources in this review and should not be repeated as settled statistics. The qualitative 2025 study on mental health and suicidality during this transition describes lived experience and clinical concern, not a quantified risk estimate.

References

• Bonaccorsi G, et al. Menopause or climacteric, just a semantic discussion or has it clinical implications? (2014), https://pubmed.ncbi.nlm.nih.gov/23998690/
• The mental health challenges, especially suicidality, experienced by women during perimenopause and menopause: A qualitative study (2025), https://pubmed.ncbi.nlm.nih.gov/40626330/

Additional claims in this article referencing specific trials, percentages, or named studies (fezolinetant trials, WHI-derived timing hypothesis data, ospemifene and prasterone trial data, sleep and cognitive cohort figures, VTE risk comparisons, and thyroid overlap prevalence) draw on the broader menopause research literature but could not be verified against a specific confirmed primary source within this review. These are flagged for verification and sourcing by clinical editorial review before publication, and should not be cited elsewhere with the specific numbers used here until confirmed against the primary papers.